F. Podo, L. Buydens, H. Degani, R. Hilhorst, E. Klipp, I. Gribbestad, et al., “Triple-Negative Breast Cancer: Present Challenges and New Perspectives,” Molecular Oncology, Vol. 4, No. 3, 2010, pp. 209-229.
 Y. Yamamoto, M. Ibusuki, M. Nakano, T. Kawasoe, R. Hiki and H. Iwase, “Clinical Significance of Basal-Like Subtype in Triple-Negative Breast Cancer,” Breast Cancer, Vol. 16, No. 4, 2009, pp. 260-267.
 T. Ruijter, J. Veeck, J. Hoon, M. Engeland and T. Tjan-Heijnen, “Characterristcs of Triple-Negative Breast Cancer,” Journal of Cancer Research and Clinical Oncology, Vol. 137, No. 2, 2011, pp. 183-192.
 R. Rouzier, C. M. Perou, W. F. Symmans, N. Ibrahim, M. Cristofanili, K. Anderson, et al., “Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy,” Clinical Cancer Research, Vol. 11, No. 16, 2005, pp. 5678-5685.
 M. Laurentiis, D. Cianniello, R. Caputo, B. Stanzione, G. Arpino, S. Cinieri, et al., “Treatment of Triple Negative Breast Cancer (TNBC): Current Options and Future Perspectives,” Cancer Treatment Reviews, Vol. 36, Suppl. 3, 2010, pp. S80-S86.
 O. Gluz, C. Liedtke, N. Gottschalk, L. Pusztai, U. Nitz and N. Harbeck, “Triple-Negative Breast Cancer-Current Status and Future Directions,” Annals of Surgical Oncology, Vol. 20, No. 12, 2009, pp. 1913-1927.
 T. Sorlie, C. M. Perou and R. Tibshirani, “Gene Expression Patterns of Breast Carcinomas Distinguish Tumor Subclasses with Clinical Implications,” Proceedings of the National Academy of Sciences of the United States, Vol. 98, No. 19, 2001, pp. 10869-10874. doi:10.1073/pnas.191367098
 E. Korshing, J. Packeisen and K. Agelopoulos, “Cytogenetic Alterations and Cytokeratin Expression Patterns in Breast Cancer: Integrating a New Model of Breast Differentiation into Cytogenetic Pathways of Breast Carcinogenesis,” Laboratory Investigation, Vol. 82, No. 11, 2002, p. 1525.
 D. Abd EI-Rehim, B. Graham and S. Pinder, “High-Throughput Protein Expression Analysis Using Tissue Microarray Technology of a Large Well-Characterised Series Identifies Biologically Distinct Classes of Breast Cancer Confirming Recent cDNA Expression Analysis,” International Journal of Cancer, Vol. 116, No. 3, 2005, pp. 340-350. doi:10.1002/ijc.21004
 Y. Yamamoto and H. Iwase, “Clinicopathological Features and Treatment Strategy for Triple-Negative Breast Cancer,” International Journal of Clinical Oncology, Vol. 15, No. 4, 2010, pp. 341-351. doi:10.1007/s10147-010-0106-1
 H. Iwase, J. Kurebayashi, H. Tsuda, T. Ohta, M. Kurosumi, T. Iwase, et al., “Clinicopathological Analyses of Triple Negative Breast Cancer Using Surveillance Data from the Registration Committee of the Japanese Breast Cancer Society,” Breast Cancer, Vol. 17, No. 2, 2010, pp. 118- 124. doi:10.1007/s12282-009-0113-0
 C. Liedtke, C. Mazouni, K. Hess, F. Andre, T. Aordai, J. Mejia, et al., “Response to Neoadjuvant Therapy and Long-Term Survival in Patients with Triple-Negative Breast Cancer,” Journal of Clinical Oncology, Vol. 26, No. 19, 2008, pp. 1275-1281. doi:10.1200/JCO.2007.14.4147
 M. C. Cheang, D. Voduc and C. Bajdik, “Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype,” Clinical Cancer Research, Vol. 14, No. 5, 2008, pp. 1368-1376. doi:10.1158/1078-0432.CCR-07-1658
 S. J. Dawson, E. Provenzano and C. Caldas, “Triple Negative Breast Cancers: Clinical and Prognostic Implications,” European Journal of Cancer, Vol. 45, No. 1, 2009, pp. 27-40. doi:10.1016/S0959-8049(09)70013-9
 T. Byrski, J. Gronwald and T. Huzarski, “Response to Neoadjuvant Chemotherapy in Women with BRCA1- Positive Breast Cancers,” Breast Cancer Research and Treatment, Vol. 108, No. 2, 2008, pp. 289-296. doi:10.1007/s10549-007-9600-1
 P. Fong, D. Boss and T. Yap, “Inhibition of Poly (ADP-Ribose) Polymerase in Tumor from BRCA Mutation Carriers,” The New England Journal of Medicine, Vol. 361, No. 2, 2009, pp. 123-134. doi:10.1056/NEJMoa0900212